Sativex is a cannabis-based oral spray prescribed in several European countries for spasticity related to multiple sclerosis. In France, this medication has marketing authorization but has never been sold in pharmacies. This situation creates legitimate confusion for patients with MS seeking a legal treatment based on therapeutic cannabis.
Marketing Authorization without Commercialization: Why Sativex Remains Unavailable in Pharmacies
You may have read that Sativex obtained its marketing authorization in France. That’s correct. A marketing authorization means that a health authority has validated the quality, safety, and efficacy of a medication.
The problem arises after this step. For a medication to reach the shelves of a pharmacy, an agreement on its price and reimbursement conditions must be reached between the laboratory and health authorities. This agreement has never been reached for Sativex in France. The medication remains legally authorized but is practically inaccessible through the standard prescription route.
This distinction between marketing authorization and actual availability is the first thing to understand. It explains why your doctor, even if convinced of the benefits of Sativex for your MS, cannot simply write a prescription and send you to the pharmacy. To learn more about Le Réseau Santé, the prescription process is still governed by specific administrative mechanisms that go beyond the simple will of the practitioner.
Medical Cannabis Experimentation in France: A Door That Has Closed
France launched a medical cannabis experimentation that allowed some patients to access cannabis-based treatments under strict medical control. This program did not specifically concern Sativex but standardized cannabis preparations in various forms.
Since March 27, 2024, no new patients can join this experimentation. Only patients already included in the program continue to receive their treatments during a transitional period.
In practice, if you were not already being monitored in this framework, this route is no longer accessible. The experimental program had its own inclusion criteria, its own products, and its own distribution channels, distinct from those of Sativex.
What Conditions Were Addressed
The experimentation targeted specific medical situations where conventional treatments had failed. Painful spasticity from multiple sclerosis was among them, alongside other indications such as certain refractory neuropathic pains or palliative care.
The prescribing physician had to work in a reference center participating in the experimentation. A general practitioner alone could not initiate the prescription.
Long-Term Regulatory Framework for Therapeutic Cannabis: What Is Still Missing
The legislator has laid the groundwork for a sustainable framework for medical cannabis in France. The goal is to move away from the experimental logic and create a stable circuit for prescription, dispensing, and reimbursement.
On paper, this should eventually pave the way for medications like Sativex. In practice, several decrees and orders necessary for the implementation of this framework have still not been published. Without these regulatory texts, doctors do not have the legal tools to prescribe, pharmacies cannot dispense, and health insurance cannot reimburse.
Role of the HAS in Evaluating Cannabis-Based Medications
The High Authority of Health has been tasked with evaluating cannabis-based medications. It adopted its evaluation method on July 23, 2025. This step conditions future decisions regarding coverage by health insurance.
The HAS’s work has been delayed by the absence of regulatory texts for implementation. The evaluation does not, by itself, provide an immediate path to obtaining Sativex. It represents a link in an administrative chain that is still incomplete.
Concrete Steps for a Patient with MS in France
In light of this situation, what options remain for a patient suffering from spasticity related to multiple sclerosis? Here are the avenues available within the current legal framework.
- Consult a neurologist specializing in MS at a reference center. This specialist knows the available anti-spastic treatments and can assess whether a request for compassionate access is feasible for your situation.
- Check with your monitoring center if you can benefit from the transitional period post-experimentation, reserved for patients already included in the program.
- Follow the regulatory developments related to the publication of the implementation decrees of the long-term framework. Patient associations, particularly in the field of multiple sclerosis, regularly relay these advancements.
- Avoid resorting to unregulated channels. CBD products sold in stores are not medications and do not have the same pharmacological profile as Sativex, which combines THC and CBD in precise proportions.
Compassionate Access and Special Authorizations
The ANSM can grant access to certain non-marketed medications in France through compassionate access programs (formerly named nominative ATU). This procedure is individual, initiated by the prescribing physician, and concerns situations where no suitable therapeutic alternative exists.
The request must go through a hospital physician, who prepares a file for the ANSM. The patient cannot undertake this process alone. The physician must justify the absence of a satisfactory alternative and document the clinical situation.
This mechanism is not automatic. Each file is examined individually. Obtaining access is never guaranteed, and processing times can vary.
The situation of Sativex in France illustrates a gap between regulatory authorization and actual access to treatment. For patients with multiple sclerosis, the journey remains complex and largely depends on the publication of the still-awaited implementation texts. Monitoring by a neurologist in a specialized center remains the most solid starting point to explore the available legal options.
